Regeneron Pharmaceuticals Announces EYLEA HD Injection 8 mg Data Presentations At AAO Reinforce Efficacy And Safety Profile In Wet Age-Related Macular Degeneration And Diabetic Macular Edema
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals (NASDAQ:REGN) announced that long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg will be presented at the American Academy of Ophthalmology (AAO) annual meeting. The data includes results from the PULSAR and PHOTON trials in wet age-related macular degeneration and diabetic macular edema. EYLEA HD is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.
November 01, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's announcement of presenting long-term outcomes and new analyses of EYLEA HD at the AAO annual meeting could potentially boost investor confidence in the company's product pipeline and partnerships.
The announcement of presenting long-term outcomes and new analyses of EYLEA HD at a prestigious event like the AAO annual meeting could be seen as a positive development by investors. This could potentially lead to increased investor confidence in Regeneron's product pipeline and partnerships, thereby possibly driving the company's stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100